CompletedPhase 3

A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer

Canada106 participantsStarted 2008-07

Plain-language summary

The primary hypothesis of this study is that regular topical oral application of Manuka Honey will reduce the severity and duration of oral mucositis in patients who are undergoing mucotoxic radiation therapy for cancer treatment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients commencing radiation therapy of 50 Gy or higher with the dosage field affecting the oral mucosa unilaterally or bilaterally (minimum 3 observable sites affected). * Patients willing and able to attend weekly assessments throughout their treatment, plus one week after completion of treatment. Exclusion Criteria: * Patients unable to understand the consent process (translators will be used if necessary so being English-speaking is not required). * Patients unable to attend the follow-up visits * Patients participating in other clinical trials which might affect the severity of mucositis * Patients allergic to honey, multiple pollens, or to celery

What they're measuring

Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had at Least One Mucositis Assessment

Timeframe: Over 7 weeks of expected duration of mucositis

Severity of Mucositis According to the Radiation Therapy Oncology Group (RTOG) for Patients Who Had a Minimum of 2 Mucositis Assessments

Timeframe: Over 7 weeks of expected duration of mucositis

Trial details

NCT IDNCT00615420

SponsorBritish Columbia Cancer Agency

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-10

Results submitted2018-10-19

View on ClinicalTrials.gov More Radiotherapy Induced Mucositis trials